| Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study V Golder, R Kandane-Rathnayake, AYB Hoi, M Huq, W Louthrenoo, Y An, ... Arthritis research & therapy 19, 1-11, 2017 | 138 | 2017 |
| Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study V Golder, R Kandane-Rathnayake, M Huq, HT Nim, W Louthrenoo, ... The Lancet Rheumatology 1 (2), e95-e102, 2019 | 111 | 2019 |
| Analysis of serum interleukin (IL)-1β and IL-18 in systemic lupus erythematosus R Mende, FB Vincent, R Kandane-Rathnayake, R Koelmeyer, E Lin, ... Frontiers in immunology 9, 1250, 2018 | 109 | 2018 |
| Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus J Godsell, I Rudloff, R Kandane-Rathnayake, A Hoi, MF Nold, EF Morand, ... Scientific reports 6 (1), 34604, 2016 | 105 | 2016 |
| Independent association of glucocorticoids with damage accrual in SLE D Apostolopoulos, R Kandane-Rathnayake, S Raghunath, A Hoi, ... Lupus science & medicine 3 (1), e000157, 2016 | 97 | 2016 |
| Adherence to asthma management guidelines by middle-aged adults with current asthma RK Kandane-Rathnayake, MC Matheson, JA Simpson, MLK Tang, ... Thorax 64 (12), 1025-1031, 2009 | 88 | 2009 |
| Discordance of patient and physician health status concerns in systemic lupus erythematosus V Golder, JJY Ooi, AS Antony, T Ko, S Morton, R Kandane-Rathnayake, ... Lupus 27 (3), 501-506, 2018 | 80 | 2018 |
| Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study D Apostolopoulos, R Kandane-Rathnayake, W Louthrenoo, SF Luo, ... The Lancet Rheumatology 2 (1), e24-e30, 2020 | 60 | 2020 |
| Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort V Golder, R Kandane-Rathnayake, AYB Hoi, M Huq, W Louthrenoo, Y An, ... Arthritis research & therapy 18, 1-9, 2016 | 58 | 2016 |
| JNK signalling in human and experimental renal ischaemia/reperfusion injury J Kanellis, FY Ma, R Kandane-Rathnayake, JP Dowling, KR Polkinghorne, ... Nephrology Dialysis Transplantation 25 (9), 2898-2908, 2010 | 58 | 2010 |
| Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study V Golder, R Kandane-Rathnayake, M Huq, W Louthrenoo, SF Luo, ... The Lancet Rheumatology 1 (2), e103-e110, 2019 | 53 | 2019 |
| Comparison of performance of specific (SLEQOL) and generic (SF36) health-related quality of life questionnaires and their associations with disease status of systemic lupus … W Louthrenoo, N Kasitanon, E Morand, R Kandane-Rathnayake Arthritis research & therapy 22, 1-12, 2020 | 44 | 2020 |
| Development of the Asia Pacific lupus collaboration cohort R Kandane‐Rathnayake, V Golder, W Louthrenoo, SF Luo, YJ Jan Wu, ... International journal of rheumatic diseases 22 (3), 425-433, 2019 | 37 | 2019 |
| The Australian and New Zealand Haemostasis Registry: ten years of data on off-licence use of recombinant activated factor VII A Zatta, Z McQuilten, R Kandane-Rathnayake, J Isbister, S Dunkley, ... Blood Transfusion 13 (1), 86, 2015 | 35 | 2015 |
| The dose–response association between nitrogen dioxide exposure and serum interleukin-6 concentrations JL Perret, G Bowatte, CJ Lodge, LD Knibbs, LC Gurrin, ... International journal of molecular sciences 18 (5), 1015, 2017 | 34 | 2017 |
| Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis M Northcott, S Jones, R Koelmeyer, J Bonin, F Vincent, ... Lupus science & medicine 9 (1), e000625, 2022 | 33 | 2022 |
| Longitudinal association of type 1 interferon-induced chemokines with disease activity in systemic lupus erythematosus KL Connelly, R Kandane-Rathnayake, M Huq, A Hoi, M Nikpour, ... Scientific reports 8 (1), 3268, 2018 | 32 | 2018 |
| ‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study R Kandane-Rathnayake, W Louthrenoo, A Hoi, SF Luo, YJJ Wu, YH Chen, ... Arthritis Research & Therapy 24 (1), 70, 2022 | 31 | 2022 |
| Analysis of serum B cell‐activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus FB Vincent, R Kandane‐Rathnayake, R Koelmeyer, AY Hoi, J Harris, ... Clinical & Translational Immunology 8 (4), e1047, 2019 | 31 | 2019 |
| Lupus low disease activity state and reduced direct health care costs in patients with systemic lupus erythematosus AL Yeo, R Koelmeyer, R Kandane‐Rathnayake, V Golder, A Hoi, M Huq, ... Arthritis Care & Research 72 (9), 1289-1295, 2020 | 30 | 2020 |
Eric MorandMonash University在 monash.edu 的电子邮件经过验证
